Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
It has been hard to predict the treatment response of HCV-infected patients to the most advanced DAA-included therapy. Using ultra-deep sequencing technology coupled with phylogenetic analysis, this study was conducted to disclose the role of viral quasispecies in determining the treatment response to DAA-included anti-HCV therapy. As a result, it was disclosed that viral quasispecies changed dynamically and certain viral isolates were selected with the introduction of DAA-based therapy. The result of the study provides better understanding of the mechanism in the appearance of DAA resistance.
|